Clarify Pharma has acquired shares to the value of £250,000 in each of Atai Life Sciences and Compass Pathways as part of its investment strategy.
Mindset Pharma and PharmaAla have entered into an exclusive sales agreement for the sale and distribution of pharmaceutical-grade psilocybin.
Biotechnology company Lusaris Therapeutics – which has a lead programme focusing on DMT for treatment-resistant depression – has launched with its Series A financing of US$60...
Biopharmaceutical company, Ceruvia Lifesciences, has announced the appointment of Stephen Hurst and David Steinberg to its Board of Directors, effective immediately.
Canadian biotechnology company, PharmAla Biotech, has submitted its pre-IND data meeting package to the US Food and Drug Administration (FDA) for its novel MDMA analogue.
Cybin has announced the graduation of highly-skilled facilitators from its EMBARK Psychedelic-Assisted Psychotherapy Training Program.
Awakn’s wholly-owned subsidiary, Awakn Oslo AS, has entered into a debt financing agreement with TD Veen AS, a family-owned, Norwegian investment company and current shareholder of...
Beckley Psytech has entered into a definitive agreement to acquire clinical-stage life science company, Eleusis Therapeutics Limited, in an all-equity transaction.
HMNC Brain Health has raised €14.3m in a funding series, raised from existing investors, including Carsten Maschmeyer, the Jahr Group and Guntard Gutmann.
Small Pharma has had its second United States patent granted by the United States Patent Office.